A team of geriatricians at Mount Sinai’s Brookdale Department of Geriatrics and Palliative Medicine has been awarded $1.25 million from the Health Resources and Services Administration and the Keith Haring Foundation to expand Mount Sinai’s interdisciplinary model of care for older patients living with HIV.
A gene recognized as the strongest risk factor for Alzheimer’s disease (AD) alters the way cholesterol moves around the brain and as we age, this altered movement likely contributes to loss of learning and memory, a team of researchers from the Icahn School of Medicine at Mount Sinai and the Massachusetts Institute of Technology (MIT) reports.
Researchers at the Icahn Mount Sinai have identified 35 genes that are particularly highly expressed in people with long-term Lyme disease. These genes could potentially be used as biomarkers to diagnose patients with the condition, which is otherwise difficult to diagnose and treat. The findings, published November 15 in the journal Cell Reports Medicine, may also lead to new therapeutic targets. The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease.
Renowned preterm birth expert to lead efforts to improve women’s health and educate and empower women researchers
A team of equity researchers at Mount Sinai’s Institute for Health Equity Research (IHER) will use a $2.5 million grant from the National Institutes of Health (NIH) to assess how unequal access to health care impacts patient health.
Mount Sinai Health System was celebrated by the U.S. Department of Health and Human Services (HHS) at the 2022 United Nations Climate Change Conference (COP27) on Thursday, November 10, for pledging ongoing action to decarbonize the health care sector and make health care facilities more resilient to the effects of climate change.
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) has recognized Mount Sinai Beth Israel for achieving meritorious outcomes for surgical patient care in 2021.
New contract provides eight years’ support for vital WTC-related health care for 9/11 workers and volunteers.
Suggests a more proactive, innate immune response among females
Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.
Honor recognizes her dedication to effectively mentoring female cardiologists
A novel metric that estimates our “burden,” or cumulative exposure, to a family of thousands of synthetic chemicals that we encounter in everyday life with potentially adverse health impacts, has been created by a team of researchers at Mount Sinai.
Mount Sinai researchers have catalogued thousands of sites in the brain where RNA is modified throughout the human lifespan in a process known as adenosine-to-inosine (A-to-I) editing, offering important new avenues for understanding the cellular and molecular mechanisms of brain development and how they factor into both health and disease.
Award honors health organizations using information technology to enhance health care and outcomes
Digital Framework Serves As Model for Large Health Systems During Future Pandemics
The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer. The latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment.
Will also serve as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine
Findings suggest exclusions to Medicaid because of immigration status may increase risk for maternal health care disparities in some immigrant populations
A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York. The findings were published October 11, 2022 in the journal Cancer Immunology Research [https://doi.org/10.1158/2326-6066.CIR-21-1075]. The study involved a twist on a type of therapy that uses immune cells known as CAR T cells. CAR T cells in current clinical use are engineered to recognize cancer cells directly and have successfully treated several blood cancers. But there have been challenges that prevent their effective use in many solid tumors.
Agreement provides framework to enhance global health care, education, and research
Harlem-based Corbin Hill Food Project secured an additional $500k funding for its Food as Medicine project in partnership with Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai, and the Institute for Family Health's Bronx Health REACH Project, bringing the total funding to $1M.
Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD, a finding that could provide insights into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
Researchers from the Icahn School of Medicine at Mount Sinai have learned that the way the brain processes the complex emotion of regret may be linked to an individual’s ability to cope with stress, and altered in psychiatric disorders like depression.
Yvette Calderon, MD, MS, Chair of Emergency Medicine at Mount Sinai Beth Israel and Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With her election, Mount Sinai has 26 faculty members in the NAM.
Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023. Dr. Fuster will continue in his roles as Physician-in-Chief of The Mount Sinai Hospital and as the Richard Gorlin, MD/Heart Research Foundation Professor at the Icahn School of Medicine at Mount Sinai.
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Program that will benefit the diverse patient population Mount Sinai serves by accelerating the development of new treatments for leading health conditions, including cardiorespiratory and psychiatric disorders, diabetes, malignancies, and infectious diseases.
Researchers have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cells.
Study results suggest the pre-frontal cortex-habenula circuit is potentially amenable for targeted interventions and prevention.
Researchers have identified the gene TDRD7 as a key regulator against influenza A virus (IAV), which causes respiratory tract infections in 5 to 20 percent of the human population.
In one of the largest single-center COVID-19 cohort studies to date, researchers at the Icahn School of Medicine at Mount Sinai, using samples collected during the peak of the pandemic in New York City, have identified a key driver of COVID-19 disease severity.
Work aims to identify neuroprotective strategies that will help treat this progressive, debilitating disorder
Mount Sinai researchers have published one of the first studies to demonstrate the importance of reactive oxygen species in maintaining stem cell function and preventing inflammation during wound repair, which could provide greater insights into the prevention and treatment of inflammatory bowel diseases (IBD), according to findings published in the journal Gut on October 3.
Researchers from the Brain Injury Research Center of Mount Sinai have been awarded $8.3 million from the National Institutes of Health (NIH) to investigate the clinical and biological features that distinguish chronic, static effects of traumatic brain injury from those associated with progressive, post-traumatic neurodegeneration.
The Icahn School of Medicine at Mount Sinai will award its inaugural 2022 Maria I. New International Prize for Biomedical Research to cancer and HIV cellular therapy pioneer Carl H. June, MD, for his groundbreaking work in immunotherapy. Dr. June is most widely known as one of the inventors of CAR T cell therapy for cancer, which has already led to FDA-approved treatments for lymphoma, leukemia, and multiple myeloma.
Mount Sinai study also shows catching up on sleep doesn’t reverse possible negative effects on cellular level
New data from the longitudinal Stress in Pregnancy Study (SIP Study) have identified earlier onset and higher rates of developmental psychopathology among children whose mothers were pregnant with them during Superstorm Sandy.
Deep learning models represent “an entirely new paradigm for studying dementia”
Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast cancer cells regulate their own metastases, fuel dissemination from the original tumor site, and determine routes to invade distant organs such as the lungs, according to a study published in Cell Reports in September.
The Mount Sinai Hospital, Mount Sinai Beth Israel, and Mount Sinai Morningside place among the world's best in Newsweek/Statista rankings.
Winners will examine impacts of COVID-19 on lung function, maternal and child health outcomes, underrepresented minority youth, and respiratory recovery.
Mount Sinai Heart leader will be recognized for his exceptional career achievements at the 34th annual conference.
Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic option for patients with these types of tumors.
Scientists at the Icahn School of Medicine at Mount Sinai in New York, the National Center for Advancing Translational Sciences (NCATS), and elsewhere have reversed the effects of several life-threatening inherited neurodegenerative diseases called lysosomal storage disorders (LSDs) in patient cells and mice.
Mount Sinai researchers have produced a high-resolution crystal structure of an enzyme essential to the survival of SARS-CoV-2, the virus that causes COVID-19. The discovery could lead to the design of new antivirals to combat current and future coronaviruses.
As the first responders to the attacks of September 11, 2001, grow older, Mount Sinai’s nationally lauded experts in aging have received a $2.4 million grant from the Centers for Disease Control and Prevention (CDC) to study how best to care for them into old age.
Results of a small, but unique research study, led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances, suggest that low-dose ketamine is generally safe, well-tolerated and effective to treat clinical symptoms in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.
Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time—they are meant to enhance the immune system’s destruction of tumor cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
